Evidence map›Paper›PMID 41157125›Full record

ReviewMolecules (Basel, Switzerland)2025

Molecular Diversity of Lupane Hybrids in Drug Design and Materials Science.

Victoria V Lipson, Maria G Shirobokova, Mustafa Kemal Gümüş, Arda Ozturkcan, Valentyn A Chebanov

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Victoria V LipsonInstitute of Functional Materials Chemistry, State Scientific Institution "Institute for Single Crystals" of NAS of Ukraine, 60 Nauky Ave., 61072 Kharkiv, Ukraine.ORCID 0000-0003-0922-1785
Maria G ShirobokovaInstitute of Functional Materials Chemistry, State Scientific Institution "Institute for Single Crystals" of NAS of Ukraine, 60 Nauky Ave., 61072 Kharkiv, Ukraine.ORCID 0000-0002-1707-5397
Mustafa Kemal GümüşScience-Technology Research and Application Center, Artvin Coruh University, Seyitler Campus, Artvin 08100, Türkiye.ORCID 0000-0001-6373-5221
Arda OzturkcanDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Istanbul Gelisim University, Istanbul 34310, Türkiye.ORCID 0000-0001-7982-6988
Valentyn A ChebanovInstitute of Functional Materials Chemistry, State Scientific Institution "Institute for Single Crystals" of NAS of Ukraine, 60 Nauky Ave., 61072 Kharkiv, Ukraine.ORCID 0000-0001-7564-778X

Funding

European Union 2022-1-TR01-KA220-HED-000089361National Academy of Sciences of Ukraine 0125U000603
6 · The paper itself

Abstract

The need for new, more effective drugs to treat cancer, infectious diseases, various parasitic infestations, and metabolic disorders requires innovative approaches to the design of promising molecules. One of these areas is the creation of hybrid structures. Lupane triterpenoids are of significant interest for such research due to their high abundance in natural sources and their renewable nature, their molecular architecture, presence of several easily modifiable functional groups, enantiomeric purity, broad spectrum of biological activity, and low toxicity. Active research into the biological properties of new pentacyclic triterpenoid derivatives, not only of the lupane series but also of the oleonane and ursane series, is evidenced by the large number of reviews and experimental studies devoted to this topic. Our interest in the modification of lupanoids stems not only from the search for biologically active compounds but also from the development of functional materials. However, the materials science aspects of lupanoid applications are virtually unknown in literature. We have tried to fill this gap and examined the possibility of using betulin derivatives to create advanced materials. The high lipophilicity and nanoscale molecular structure of these compounds make them highly promising as chiral dopants in liquid crystal compositions and organogel components.

Indexed as

Drug DesignTriterpenesHumansMolecular StructurePentacyclic TriterpeneslupanePentacyclic TriterpenesTriterpenesbetulinic acidbiological activitychiral dopantsliquid crystalslupane triterpenoidsorganogels

Identifiers

PMID41157125
PMCPMC12566002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.